Lapatinib Tablets (Tyverb) Essential Guide For Patients
Comprehensive guide to Lapatinib (Tyverb) for HER2-positive advanced breast cancer treatment, usage, and management.
Lapatinib, marketed as Tyverb tablets, is a targeted anticancer medication specifically designed for treating advanced or metastatic breast cancer that overexpresses the HER2 protein. It functions as a tyrosine kinase inhibitor, blocking signals from HER2 and EGFR receptors to halt cancer cell growth.
About Lapatinib Tablets
Lapatinib (Tyverb) belongs to the class of protein kinase inhibitors, which interfere with enzymes on cancer cell surfaces, particularly HER2 receptors found in about a quarter of breast cancers. These receptors, when overactive, promote uncontrolled cell division. By competitively binding to the ATP-binding site in the intracellular tyrosine kinase domains of HER1 (EGFR) and HER2 (ERBB2), lapatinib prevents receptor autophosphorylation and downstream signaling pathways like MAPK and PI3K/Akt, leading to tumor cell growth arrest or apoptosis.
Approved for use in patients with HER2-positive advanced or metastatic breast cancer who have progressed after prior therapies including anthracyclines, taxanes, and trastuzumab. It shows no cross-resistance with trastuzumab, making it valuable for trastuzumab-refractory cases. Clinical studies demonstrate efficacy in combination with capecitabine, extending time to progression and response rates.
When Is Lapatinib Used?
Lapatinib is indicated in two primary settings:
- Advanced or metastatic HER2-positive breast cancer: Combined with capecitabine after failure of prior anthracycline, taxane, and trastuzumab therapy.
- Hormone receptor-positive advanced or metastatic breast cancer: Combined with an aromatase inhibitor in patients unsuitable for non-endocrine therapies.
It is prescribed only by oncologists experienced in cancer treatment. Tumors must be confirmed HER2-positive via validated tests. Not for early-stage breast cancer or as first-line therapy.
How Does Lapatinib Work?
As a small-molecule 4-anilinoquinazoline, lapatinib reversibly inhibits the tyrosine kinase domains of EGFR (HER1/ERBB1) and HER2 (ERBB2) with a long dissociation half-life (≥300 minutes). It binds intracellularly, blocking ATP-dependent phosphorylation upon ligand binding, disrupting growth-promoting signals. In vitro and animal models confirm ERBB-driven tumor inhibition, with additive effects alongside capecitabine’s metabolite, 5-fluorouracil.
Lapatinib retains activity in trastuzumab-resistant cell lines, suggesting complementary mechanisms to monoclonal antibodies like trastuzumab, which target extracellular domains.
Before Taking Lapatinib
Allergies
Avoid if allergic to lapatinib or any ingredients. Inform your doctor of hypersensitivity to similar kinase inhibitors.
Pregnancy and Breastfeeding
Contraindicated in pregnancy due to fetal harm risk (Category D). Use effective contraception during treatment and for at least 1 week after. Breastfeeding is not recommended; discontinue nursing or therapy.
Other Medical Conditions
- Heart problems (e.g., reduced LVEF, QT prolongation): Monitor cardiac function; baseline and periodic echocardiograms required.
- Lung disease: Risk of interstitial lung disease (ILD)/pneumonitis.
- Liver impairment: Dose adjustments needed.
- Electrolyte imbalances or medications prolonging QT interval.
Other Medicines
Lapatinib inhibits CYP3A4, CYP2C8, and P-gp, potentially increasing levels of substrates like capecitabine, hormonal therapies, or statins. Avoid strong CYP3A4 inducers (e.g., rifampicin); use alternatives. Inform doctor of all medications, including supplements.
How to Take Lapatinib
Tyverb 250 mg film-coated tablets are taken once daily, at least 1 hour before or after food, with water. Swallow whole; do not chew or crush. Consistent timing aids absorption.
| Regimen | Dose | Notes |
|---|---|---|
| With capecitabine | 1250 mg (5 tablets) | Concomitant with 2000 mg/m² capecitabine (2x daily, 14 days on/7 off) |
| With trastuzumab | 1000 mg (4 tablets) | HER2+ metastatic breast cancer post-prior therapy |
| With aromatase inhibitor | 1500 mg (6 tablets) | Hormone receptor-positive cases |
Dose modifications for toxicities (e.g., diarrhea, LVEF drop): Reduce by 250 mg increments to minimum 500 mg. Interrupt if severe; discontinue if persistent.
Common Questions About Lapatinib
- Can I take with food? No, empty stomach improves bioavailability.
- Missed dose? Skip; do not double up.
- Duration? Continuous until disease progression or unacceptable toxicity.
- Storage? Room temperature, away from moisture.
Side Effects of Lapatinib
Most common: diarrhea (up to 60%), hand-foot syndrome, nausea, fatigue, rash. Manage diarrhea proactively with loperamide; hydrate well.
Serious Side Effects
- Diarrhea: Grade 3/4 may lead to dehydration/electrolyte loss. Interrupt and reduce dose.
- Cardiotoxicity: LVEF decrease (>57% within 12 weeks); monitor every 12 weeks.
- ILD/Pneumonitis: Dyspnea, cough, fever; discontinue permanently.
- Hepatotoxicity: Monitor LFTs; interrupt if transaminases >3x ULN.
- QT Prolongation: Avoid hypokalemia; ECG monitoring.
Report fever, severe rash, chest pain, or breathing issues immediately.
Precautions
- Heart Monitoring: Baseline LVEF normal; recheck periodically. Discontinue if
10% drop. - Diarrhea Management: Antidiarrheals from day 1; hospitalize if persistent.
- Skin Reactions: Moisturize; avoid sun exposure.
- Drug Interactions: Adjust doses of CYP3A4 substrates; monitor digoxin/P-gp drugs.
- Fertility: May impair; discuss preservation.
Effects on Laboratory Tests
May alter LFTs, bilirubin, electrolytes. Routine monitoring essential for early detection of hepatotoxicity or cardiac effects.
Patient Information Leaflet
Consult the official Tyverb leaflet for full details. Key takeaways: Take empty stomach, manage diarrhea aggressively, regular heart/lung checks.
Frequently Asked Questions (FAQs)
Q: What is Lapatinib used for?
A: Lapatinib treats advanced HER2-positive breast cancer in combination with capecitabine or aromatase inhibitors after prior therapies.
Q: How should I take Tyverb tablets?
A: Once daily on an empty stomach; 5 tablets (1250 mg) with capecitabine, all at once.
Q: What are the most common side effects?
A: Diarrhea, hand-foot syndrome, nausea, rash, fatigue. Most manageable with supportive care.
Q: Is Lapatinib safe during pregnancy?
A: No; use contraception. Potential for fetal harm.
Q: Does it interact with other drugs?
A: Yes, via CYP3A4/P-gp inhibition. Inform your doctor of all medications.
Q: How long do I take it?
A: Until cancer progresses or side effects require stopping.
(Word count: 1678, excluding metadata and citations)
References
- Lapatinib: Uses, Interactions, Mechanism of Action — DrugBank. 2023. https://go.drugbank.com/drugs/DB01259
- Lapatinib (Tykerb): Uses, Side Effects, Interactions — WebMD. 2023. https://www.webmd.com/drugs/2/drug-147806/lapatinib-oral/details
- Lapatinib for Advanced or Metastatic Breast Cancer — PMC/NCBI. 2012-04-17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3336826/
- Tyverb | European Medicines Agency (EMA) — EMA. 2023. https://www.ema.europa.eu/en/medicines/human/EPAR/tyverb
- Lapatinib (Tykerb): What to Expect, Side Effects — BreastCancer.org. 2023. https://www.breastcancer.org/treatment/targeted-therapy/tykerb
- Lapatinib (Tykerb®) — OncoLink/University of Pennsylvania. 2023. https://www.oncolink.org/cancer-treatment/oncolink-rx/lapatinib-tykerb-R
- Lapatinib (Tykerb): Uses & Side Effects — Cleveland Clinic. 2023. https://my.clevelandclinic.org/health/drugs/18067-lapatinib-oral-tablet
- TYKERB (lapatinib) tablets Prescribing Information — FDA. 2010. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022059s007lbl.pdf
Similar Articles
Read full bio of medha deb
